Which are the causes of Fibrous Dysplasia?

TL;DR: Fibrous dysplasia is caused by a post-zygotic somatic mutation in the GNAS gene, which occurs randomly after conception and is not inherited from parents. This mutation disrupts bone-forming cells, causing them to produce abnormal, fibrous tissue instead of healthy, mature bone.

What is the underlying cause of Fibrous Dysplasia?

The primary cause of fibrous dysplasia is a genetic mutation that occurs spontaneously in a single cell during early fetal development. This is a "somatic" mutation, meaning it is not present in the sperm or egg cells and is not passed down from parents to children. Essentially, the GNAS gene—which acts as a master switch for cell signaling—becomes "stuck" in the "on" position. This constant signal forces bone-forming cells (osteoblasts) to stop maturing properly. Instead of creating hard, mineralized bone, these cells produce immature, disorganized fibrous tissue, which is why fibrous dysplasia leads to weakened, misshapen, or fragile bones.

Is Fibrous Dysplasia a hereditary condition?

No, fibrous dysplasia is not hereditary. Because the GNAS mutation happens after the egg is fertilized, it is not found in the DNA of every cell in the body; rather, it is present only in the specific tissues affected by the disease. This is often referred to as mosaicism. Because the mutation is not in the reproductive cells, individuals with fibrous dysplasia do not pass the condition on to their offspring. There is no known way to prevent this mutation, as it appears to be a random biological event.

What are the risk factors and triggers?

It is important to distinguish between the cause and the risk factors for fibrous dysplasia. The cause is the specific GNAS mutation described above. Currently, there are no known environmental triggers, dietary factors, or lifestyle choices that are proven to cause or exacerbate the condition. It is not caused by an autoimmune reaction, an infection, or a metabolic disorder. Clinical research indicates that the severity and extent of fibrous dysplasia are determined solely by which cells carry the mutation and when that mutation occurred during development.

How does the mutation affect bone health?

To understand how the GNAS mutation impacts the body, think of the bone-building process like a construction site. In a healthy bone, there is a clear blueprint for how to build a strong structure. In fibrous dysplasia, the GNAS mutation acts like a faulty foreman who ignores the blueprints and forces workers to use "soft" materials instead of steel and concrete. Key impacts include:

• Disrupted Maturation: Bone-forming cells fail to mineralize, leaving the bone tissue soft and malleable.


• Structural Weakness: The resulting "fibrous" areas are unable to withstand normal physical stress, increasing the risk of fractures or deformity.


• Variable Presentation: Because the mutation can occur at different times during development, the disease can affect a single bone (monostotic) or multiple bones (polyostotic).

What is the current state of research?

Medical researchers are actively investigating why the GNAS mutation affects certain cell types more than others. Currently, 280 people with fibrous dysplasia have joined the DiseaseMaps community, providing valuable data that helps researchers understand the patient experience and the variability of the condition. Ongoing studies are focused on targeted therapies that might eventually help "reset" the signaling pathways in the affected bone cells, though these remain in the experimental stage.

Next steps

• Consult an orthopedic specialist or an endocrinologist who has specific clinical experience with bone dysplasia.


• Request a referral to a genetic counselor if you have questions about the nature of somatic mutations.


• Join the DiseaseMaps.org community to connect with others and share experiences regarding management and care.


• Monitor for bone pain or changes in mobility and discuss these symptoms with your physician immediately.

Medical disclaimer: This information is for educational purposes only and should not replace professional medical advice, diagnosis, or treatment from a qualified healthcare provider.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases (GARD) Information Center: Fibrous Dysplasia.


• Orphanet: Monostotic and Polyostotic Fibrous Dysplasia.


• Online Mendelian Inheritance in Man (OMIM): #174800 Fibrous Dysplasia of Bone.


• Fibrous Dysplasia Foundation: Clinical information and patient resources.